Tag: VIVA 2025
“We need to look at the totality of evidence”: VIVA panellists...
A focused session at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA) homed in on the latest findings from the...
CAVT with anticoagulation significantly improves functional outcomes in PE patients, RCT...
Mechanical thrombectomy by means of computer-assisted vacuum thrombectomy (CAVT) using the 16Fr Lightning Flash system (Penumbra) along with anticoagulation for acute-to-intermediate pulmonary embolism (PE)...
Three-year data support drug-eluting resorbable scaffold as “durable, effective endovascular treatment...
Three-year data from the LIFE-BTK randomised controlled trial, presented today at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA), demonstrate the...
PE thrombectomy: ENGULF pivotal study meets safety and efficacy endpoints
Full results from the ENGULF pivotal study of the Hēlo thrombectomy system (Endovascular Engineering) in acute intermediate risk pulmonary embolism (PE) patients demonstrated a...
Results from sex-specific analysis of Surmodics’ PROWL registry revealed
Surmodics has announced that results from a sex-specific analysis of 160 real-world acute, subacute, and chronic thrombotic limb ischaemia patients from its PROWL registry...
